Trusted Resource for Clinical Trials, Protocols & Progress
The shift toward remote clinical trial operations has made online site visits a standard practice. These visits—conducted virtually by Clinical Research Associates (CRAs) or monitors—play a critical role in verifying protocol adherence, reviewing source data, and assessing trial conduct. However, successful execution depends heavily on how well the site staff are prepared for these visits.
Click to read the full article.
The evolution of decentralized clinical trials has propelled virtual site visits from an emergency workaround during the COVID-19 pandemic to a long-term solution for remote oversight. However, regulatory acceptability of such visits depends on strict adherence to Good Clinical Practice (GCP), documented procedures, and quality systems supporting remote operations.
Click to read the full article.
Remote clinical trials have redefined how site monitoring is executed, with virtual site visits becoming a common alternative to traditional on-site interactions. While remote models offer flexibility and cost-efficiency, they introduce new complexities in determining the appropriate frequency of site oversight. Regulatory bodies such as the FDA, EMA, and ICH GCP emphasize that visit intervals must be justified by study risk, trial phase, and data quality trends—not by routine scheduling alone.
Click to read the full article.
As decentralized and hybrid clinical trial models become standard, video conferencing tools have emerged as a primary mechanism for conducting virtual site visits. These tools are used to facilitate discussions between site personnel and monitors, perform remote source data verification (rSDV), and document interactions for inspection readiness. However, not all video conferencing platforms are built to meet regulatory expectations set by FDA, EMA, and ICH GCP guidelines.
Click to read the full article.
Virtual site visits have become a standard tool in remote and hybrid clinical trial oversight. They facilitate communication, oversight, and source data review without the need for physical presence. However, with this convenience comes a new set of operational and compliance challenges. Technical disruptions, communication failures, data access limitations, and documentation inconsistencies are frequently reported in audits involving virtual monitoring activities.
Click to read the full article.
As decentralized and hybrid clinical trials gain traction, electronic informed consent (eConsent) has become a cornerstone of remote patient onboarding. Traditional paper-based consent processes are ill-suited for remote setups, and regulators have increasingly recognized the importance of digitized alternatives that preserve compliance, clarity, and participant autonomy.
Click to read the full article.
As remote and decentralized trials become increasingly common, traditional methods of presenting informed consent through static documents are no longer sufficient. Multimedia-enabled eConsent tools—featuring videos, interactive graphics, quizzes, and voiceovers—enhance comprehension, especially for diverse and multilingual populations. They also align with regulatory expectations for ensuring patient understanding before enrollment.
Click to read the full article.
The adoption of remote eConsent has transformed how participants engage with clinical trials, particularly in decentralized and hybrid models. With the shift from traditional paper-based consent processes, regulatory authorities have recognized the need to establish clear guidelines for ensuring participant understanding, ethical enrollment, and data integrity in virtual environments.
Click to read the full article.
In decentralized and hybrid clinical trials, remote patient enrollment has become increasingly common. With this shift comes the challenge of verifying a participant’s identity during the electronic informed consent (eConsent) process. Regulatory agencies, including the FDA and EMA, emphasize that the identity of clinical trial subjects must be verified with the same rigor as in-person enrollment, even in remote settings.
Click to read the full article.
The rise of decentralized and hybrid clinical trials has made the electronic informed consent (eConsent) process more critical than ever. However, standalone eConsent platforms create a data silo that limits visibility and auditability. Regulatory agencies, including the FDA and EMA, expect seamless integration of eConsent data with Electronic Data Capture (EDC) systems to ensure traceability, prevent protocol deviations, and facilitate inspection readiness.
Click to read the full article.
